구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||||
|---|---|---|---|---|---|
Overview Program | Humira (adalimumab) | Enbrel (etanercept) | Stelara (ustekinumab) | Tremfya (guselkumab) | Bimzelx (bimekizumab) |
Overview Company | AbbVie | Amgen / Pfizer | Johnson & Johnson | Johnson & Johnson | UCB |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | TNF-α | TNF (decoy receptor) | IL-12 / IL-23 (p40) | IL-23 p19 | IL-17A / IL-17F |
Overview Indication | Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA | RA, PsA, AS, plaque psoriasis, JIA | Psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis | Plaque psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease | Plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | novel object recognition test | novel ADAM17 inhibitor drugs to block soluble TNF-α production in inflammatory diseases | Novel therapeutic avenues, including TYK2 and HDAC inhibitors, as well as nanotechnology-based delivery systems, show encoura | Leaving IL-12 intact preserves Th1 antimicrobial immunity while shutting down the Th17 axis, which is why durability is high and infection signals are low. | IL-17F contributes independently to tissue inflammation, so blocking it as well raises the ceiling on complete skin clearance. |
Positioning Known limitation | Anti-drug antibodies, TNF-independent inflammation, and immunogenicity lowering trough levels. | Anti-drug antibodies (lower vs mAb TNF inhibitors), non-TNF pathways. | IL-23 axis escape, anti-drug antibodies, and non-IL-12/23 inflammation. | Anti-drug antibodies are rare; non-IL-23-driven fibrostenotic disease does not respond. | Anti-drug antibodies and non-IL-17-driven inflammatory phenotypes. |
Positioning Development positioning | — | — | — | IL-23 class benchmark alongside Skyrizi, now with the broadest IBD label progression. | Efficacy leader in psoriasis clearance versus IL-17A-only and IL-23 agents. |
MoA Mechanism | Adalimumab binds specifically to TNF-α and blocks its interaction with p55 and p75 cell-surface TNF receptors, neutralizing TNF-mediated inflammatory cascades (IL-6, adhesion molecules, acute-phase proteins). | Etanercept is a dimeric fusion protein of human p75 TNF receptor linked to IgG1 Fc; it binds TNF-α and lymphotoxin-α, preventing receptor activation and downstream NF-κB inflammatory signaling. | Ustekinumab binds the p40 subunit shared by IL-12 and IL-23, preventing their interaction with IL-12Rβ1 receptor and downstream Th1/Th17 differentiation and cytokine production. | Neutralizes IL-23 by binding p19, blocking IL-23R signaling and downstream Th17/Th22 differentiation, IL-17 production, and tissue inflammation in skin, joints, and gut mucosa. | Binds IL-17A and IL-17F, preventing engagement of the IL-17RA/RC complex and shutting down downstream keratinocyte and synovial inflammatory signaling more completely than IL-17A blockade alone. |
MoA Biomarker | CRP, ESR, disease-specific scores (DAS28, PASI, Mayo for IBD). | DAS28, PASI, CRP. | biomarkers but require external validation in independent cohorts | PASI/IGA in psoriasis, ACR20 in PsA, endoscopic improvement and fecal calprotectin in IBD. | PASI/IGA response, hs-CRP in axial disease. |
PK/PD Half-life | ~14–19 days (SC) | 30 h | 19 h | ~15–18 days | ~23 days |
PK/PD Species | Rat, xenografts, which corroborat, CRP reduction, clinical remission scores | Rat, CRP, joint counts, skin scores | Mouse, Skin clearance (PASI75/90), endoscopic response in IBD | Cynomolgus monkey, PASI 90/100, ACR20/50, endoscopic remission, serum IL-17A/IL-22 | Cynomolgus monkey, PASI 90/100, HiSCR in HS, ASAS40 in axSpA |
PK/PD Animal (cat.) | Rat | Rat, In vitro | Mouse | Human, NHP | Human, NHP, In vitro |
PK/PD Experiment | pd | pharmacokinetic | Pharmacokinetic | Pharmacokinetic | pd |
Toxicology Species | Cynomolgus monkey, Rat, xenografts, which corroborat | Rat | Cynomolgus monkey, Mouse | Mouse, Pig | Cynomolgus monkey |
Toxicology Animal (cat.) | NHP | — | — | — | — |
Toxicology Major finding | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. | Injection-site reactions, infections, rare demyelination and lupus-like syndrome. | Infections, reversible posterior leukoencephalopathy syndrome (rare), hypersensitivity. | Upper respiratory infection, headache, and injection-site reactions dominate. Serious infection and malignancy signals have stayed low across long-term psoriasis follow-up. | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. |
Toxicology CRS | N/A | N/A | N/A | N/A | N/A |
Clinical Safety signal | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. | Injection-site reactions, infections, rare demyelination and lupus-like syndrome. | Infections, reversible posterior leukoencephalopathy syndrome (rare), hypersensitivity. | Upper respiratory infection, headache, and injection-site reactions dominate. Serious infection and malignancy signals have stayed low across long-term psoriasis follow-up. | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. |
Clinical Selected reported efficacy | — | 73.4% | PASI75 67% | — | — |
Clinical PASI75 | — | PASI 75 response rate at Week 12. | 67% | — | PASI 100 than secukinumab at week 16 and mai |
Clinical Result source | ClinicalTrials.gov NCT02405780 | ClinicalTrials.gov NCT01891864 | PHOENIX | — | BE RADIANT (NCT03536884) / BE VIVID / BE SURE |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT02405780 | NCT01891864 | PHOENIX | — | NCT03536884 |
Preclinical Animal (cat.) | — | Rat | — | Mouse | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||||
|---|---|---|---|---|---|
Overview Program | Humira (adalimumab) | Enbrel (etanercept) | Stelara (ustekinumab) | Tremfya (guselkumab) | Bimzelx (bimekizumab) |
Overview Company | AbbVie | Amgen / Pfizer | Johnson & Johnson | Johnson & Johnson | UCB |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | TNF-α | TNF (decoy receptor) | IL-12 / IL-23 (p40) | IL-23 p19 | IL-17A / IL-17F |
Overview Indication | Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA | RA, PsA, AS, plaque psoriasis, JIA | Psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis | Plaque psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease | Plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | novel object recognition test | novel ADAM17 inhibitor drugs to block soluble TNF-α production in inflammatory diseases | Novel therapeutic avenues, including TYK2 and HDAC inhibitors, as well as nanotechnology-based delivery systems, show encoura | Leaving IL-12 intact preserves Th1 antimicrobial immunity while shutting down the Th17 axis, which is why durability is high and infection signals are low. | IL-17F contributes independently to tissue inflammation, so blocking it as well raises the ceiling on complete skin clearance. |
Positioning Known limitation | Anti-drug antibodies, TNF-independent inflammation, and immunogenicity lowering trough levels. | Anti-drug antibodies (lower vs mAb TNF inhibitors), non-TNF pathways. | IL-23 axis escape, anti-drug antibodies, and non-IL-12/23 inflammation. | Anti-drug antibodies are rare; non-IL-23-driven fibrostenotic disease does not respond. | Anti-drug antibodies and non-IL-17-driven inflammatory phenotypes. |
Positioning Development positioning | — | — | — | IL-23 class benchmark alongside Skyrizi, now with the broadest IBD label progression. | Efficacy leader in psoriasis clearance versus IL-17A-only and IL-23 agents. |
MoA Mechanism | Adalimumab binds specifically to TNF-α and blocks its interaction with p55 and p75 cell-surface TNF receptors, neutralizing TNF-mediated inflammatory cascades (IL-6, adhesion molecules, acute-phase proteins). | Etanercept is a dimeric fusion protein of human p75 TNF receptor linked to IgG1 Fc; it binds TNF-α and lymphotoxin-α, preventing receptor activation and downstream NF-κB inflammatory signaling. | Ustekinumab binds the p40 subunit shared by IL-12 and IL-23, preventing their interaction with IL-12Rβ1 receptor and downstream Th1/Th17 differentiation and cytokine production. | Neutralizes IL-23 by binding p19, blocking IL-23R signaling and downstream Th17/Th22 differentiation, IL-17 production, and tissue inflammation in skin, joints, and gut mucosa. | Binds IL-17A and IL-17F, preventing engagement of the IL-17RA/RC complex and shutting down downstream keratinocyte and synovial inflammatory signaling more completely than IL-17A blockade alone. |
MoA Biomarker | CRP, ESR, disease-specific scores (DAS28, PASI, Mayo for IBD). | DAS28, PASI, CRP. | biomarkers but require external validation in independent cohorts | PASI/IGA in psoriasis, ACR20 in PsA, endoscopic improvement and fecal calprotectin in IBD. | PASI/IGA response, hs-CRP in axial disease. |
PK/PD Half-life | ~14–19 days (SC) | 30 h | 19 h | ~15–18 days | ~23 days |
PK/PD Species | Rat, xenografts, which corroborat, CRP reduction, clinical remission scores | Rat, CRP, joint counts, skin scores | Mouse, Skin clearance (PASI75/90), endoscopic response in IBD | Cynomolgus monkey, PASI 90/100, ACR20/50, endoscopic remission, serum IL-17A/IL-22 | Cynomolgus monkey, PASI 90/100, HiSCR in HS, ASAS40 in axSpA |
PK/PD Animal (cat.) | Rat | Rat, In vitro | Mouse | Human, NHP | Human, NHP, In vitro |
PK/PD Experiment | pd | pharmacokinetic | Pharmacokinetic | Pharmacokinetic | pd |
Toxicology Species | Cynomolgus monkey, Rat, xenografts, which corroborat | Rat | Cynomolgus monkey, Mouse | Mouse, Pig | Cynomolgus monkey |
Toxicology Animal (cat.) | NHP | — | — | — | — |
Toxicology Major finding | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. | Injection-site reactions, infections, rare demyelination and lupus-like syndrome. | Infections, reversible posterior leukoencephalopathy syndrome (rare), hypersensitivity. | Upper respiratory infection, headache, and injection-site reactions dominate. Serious infection and malignancy signals have stayed low across long-term psoriasis follow-up. | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. |
Toxicology CRS | N/A | N/A | N/A | N/A | N/A |
Clinical Safety signal | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. | Injection-site reactions, infections, rare demyelination and lupus-like syndrome. | Infections, reversible posterior leukoencephalopathy syndrome (rare), hypersensitivity. | Upper respiratory infection, headache, and injection-site reactions dominate. Serious infection and malignancy signals have stayed low across long-term psoriasis follow-up. | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. |
Clinical Selected reported efficacy | — | 73.4% | PASI75 67% | — | — |
Clinical PASI75 | — | PASI 75 response rate at Week 12. | 67% | — | PASI 100 than secukinumab at week 16 and mai |
Clinical Result source | ClinicalTrials.gov NCT02405780 | ClinicalTrials.gov NCT01891864 | PHOENIX | — | BE RADIANT (NCT03536884) / BE VIVID / BE SURE |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT02405780 | NCT01891864 | PHOENIX | — | NCT03536884 |
Preclinical Animal (cat.) | — | Rat | — | Mouse | — |
추천 비교
추천 비교